Huu Phuc Nguyen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/545454/publications.pdf

Version: 2024-02-01

117 papers	12,039 citations	94433 37 h-index	26613 107 g-index
121 all docs	121 docs citations	121 times ranked	24804 citing authors

#	Article	IF	Citations
1	Adenoma and colorectal cancer risks in Lynch syndrome, Lynchâ€like syndrome and familial colorectal cancer type X. International Journal of Cancer, 2022, 150, 56-66.	5.1	2
2	DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family. Brain, 2022, 145, 3968-3984.	7.6	4
3	Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in ‹scp›AML‹/scp›/‹scp›MDS‹/scp› patients. International Journal of Cancer, 2022, 150, 1998-2011.	5.1	32
4	Huntington disease update: new insights into the role of repeat instability in disease pathogenesis. Medizinische Genetik, 2022, 33, 293-300.	0.2	0
5	Regulation of Cell Delamination During Cortical Neurodevelopment and Implication for Brain Disorders. Frontiers in Neuroscience, 2022, 16, 824802.	2.8	3
6	Environmental stimulation in Huntington disease patients and animal models. Neurobiology of Disease, 2022, 171, 105725.	4.4	8
7	Calpains as novel players in the molecular pathogenesis of spinocerebellar ataxia type 17. Cellular and Molecular Life Sciences, 2022, 79, 262.	5.4	6
8	Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients. Journal of Infectious Diseases, 2022, 226, 1608-1615.	4.0	12
9	Differential Cellular Balance of Olfactory and Vomeronasal Epithelia in a Transgenic BACHD Rat Model of Huntingtonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 7625.	4.1	0
10	Intranuclear immunostaining-based FACS protocol from embryonic cortical tissue. STAR Protocols, 2021, 2, 100318.	1.2	10
11	The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntingtonâ€™s Disease. Pharmaceuticals, 2021, 14, 257.	3.8	1
12	Molecular Profiling Reveals Involvement of ESCO2 in Intermediate Progenitor Cell Maintenance in the Developing Mouse Cortex. Stem Cell Reports, 2021, 16, 968-984.	4.8	5
13	Polygenic Scores for Cognitive Abilities and Their Association with Different Aspects of General Intelligenceâ€”A Deep Phenotyping Approach. Molecular Neurobiology, 2021, 58, 4145-4156.	4.0	17
14	Teaching Video NeuroImages: New STUB1 Variant Causes Chorea, Tremor, Dystonia, Myoclonus, Ataxia, Depression, Cognitive Impairment, Epilepsy, and Superficial Siderosis. Neurology, 2021, 97, 10.1212/WNL.0000000000012264.	1.1	4
15	Mapping of domain-mediated protein-protein interaction by SPOT peptide assay. STAR Protocols, 2021, 2, 100503.	1.2	3
16	H3 acetylation selectively promotes basal progenitor proliferation and neocortex expansion. Science Advances, 2021, 7, eabc6792.	10.3	16
17	Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD. Neuropharmacology, 2020, 162, 107812.	4.1	12
18	Impaired dopamine- and adenosine-mediated signaling and plasticity in a novel rodent model for DYT25 dystonia. Neurobiology of Disease, 2020, 134, 104634.	4.4	22

#	Article	IF	Citations
19	Ageâ€related alteration of emotional regulation in the BACHD rat model of Huntington disease. Genes, Brain and Behavior, 2020, 19, e12633.	2.2	1
20	Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18661-18669.	7.1	18
21	Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. Genetics in Medicine, 2020, 22, 2108-2113.	2.4	32
22	Patterns of CAG repeat instability in the central nervous system and periphery in Huntingtonâ€™s disease and in spinocerebellar ataxia type 1. Human Molecular Genetics, 2020, 29, 2551-2567.	2.9	69
23	Validation of behavioral phenotypes in the BACHD rat model. Behavioural Brain Research, 2020, 393, 112783.	2.2	5
24	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. BMC Cancer, 2019, 19, 787.	2.6	10
25	Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate. Biochemical Pharmacology, 2019, 168, 305-318.	4.4	22
26	bHLH Transcription Factor Math6 Antagonizes TGF-Î² Signalling in Reprogramming, Pluripotency and Early Cell Fate Decisions. Cells, 2019, 8, 529.	4.1	8
27	Killing Two Angry Birds with One Stone: Autophagy Activation by Inhibiting Calpains in Neurodegenerative Diseases and Beyond. BioMed Research International, 2019, 2019, 1-13.	1.9	18
28	Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease. Molecular Therapy - Methods and Clinical Development, 2019, 15, 343-358.	4.1	38
29	The BACHD rat model of Huntington disease shows slowed learning in a Go/No-Go-like test of visual discrimination. Behavioural Brain Research, 2019, 359, 116-126.	2.2	2
30	Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease. Neuropharmacology, 2018, 133, 94-106.	4.1	19
31	Environment-dependent striatal gene expression in the BACHD rat model for Huntington disease. Scientific Reports, 2018, 8, 5803.	3.3	10
32	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
33	Home-cage anxiety levels in a transgenic rat model for Spinocerebellar ataxia type 17 measured by an approach-avoidance task: The light spot test. Journal of Neuroscience Methods, 2018, 300, 48-58.	2.5	10
34	B05â€...Environment-driven influences and neuroprotection in the BACHD RAT model for huntington disease. , 2018, , .		0
35	Dynamic nuclear envelope phenotype in rats overexpressing mutated human torsinA protein. Biology Open, 2018, 7, .	1.2	2
36	Sexual behavior and testis morphology in the BACHD rat model. PLoS ONE, 2018, 13, e0198338.	2.5	8

#	Article	IF	Citations
37	Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8765-E8774.	7.1	47
38	The Alteration of Emotion Regulation Precedes the Deficits in Interval Timing in the BACHD Rat Model for Huntington Disease. Frontiers in Integrative Neuroscience, 2018, 12, 14.	2.1	8
39	BACHD rats expressing full-length mutant huntingtin exhibit differences in social behavior compared to wild-type littermates. PLoS ONE, 2018, 13, e0192289.	2.5	13
40	Anxiety and risk assessment-related traits in a rat model of Spinocerebellar ataxia type 17. Behavioural Brain Research, 2017, 321, 106-112.	2.2	5
41	Dysregulation of gene expression in the striatum of BACHD rats expressing full-length mutant huntingtin and associated abnormalities on molecular and protein levels. Neuropharmacology, 2017, 117, 260-272.	4.1	13
42	Altered reactivity of central amygdala to GABAAR antagonist in the BACHD rat model of Huntington disease. Neuropharmacology, 2017, 123, 136-147.	4.1	10
43	A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3. Brain, 2017, 140, 1280-1299.	7.6	33
44	Capturing schizophrenia-like prodromal symptoms in a spinocerebellar ataxia-17 transgenic rat. Journal of Psychopharmacology, 2017, 31, 461-473.	4.0	5
45	The BACHD Rat Model of Huntington Disease Shows Specific Deficits in a Test Battery of Motor Function. Frontiers in Behavioral Neuroscience, 2017, 11, 218.	2.0	23
46	The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory. PLoS ONE, 2017, 12, e0169051.	2.5	18
47	Reduced cell size, chromosomal aberration and altered proliferation rates are characteristics and confounding factors in the STHdh cell model of Huntington disease. Scientific Reports, 2017, 7, 16880.	3.3	17
48	Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease. PLoS ONE, 2017, 12, e0173232.	2.5	11
49	Impaired Decision Making and Loss of Inhibitory-Control in a Rat Model of Huntington Disease. Frontiers in Behavioral Neuroscience, 2016, 10, 204.	2.0	23
50	Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. Journal of Hepatology, 2016, 65, 849-855.	3.7	75
51	B42â€...Early olfactory behaviour deficits associated with olfactory bulb atrophy and caspase-8 activation in HD rodent models. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A24.1-A24.	1.9	0
52	C6â€...Novel behavioural readouts of the bachd rat in the reeperbahn and barnes maze tests. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A28.3-A29.	1.9	0
53	Activation of AMPK-induced autophagy ameliorates Huntington disease pathology inÂvitro. Neuropharmacology, 2016, 108, 24-38.	4.1	59
54	C7â€...The bachd rat model of huntingtonâ€™s disease shows signs of fronto-striatal dysfunction in two skinner box-based tests of short-term memory. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A29.1-A29.	1.9	0

#	Article	IF	Citations
55	The calpain-suppressing effects of olesoxime in Huntington's disease. Rare Diseases (Austin, Tex), 2016, 4, e1153778.	1.8	12
56	Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Human Molecular Genetics, 2016, 25, ddw122.	2.9	62
57	Automated quantitative analysis to assess motor function in different rat models of impaired coordination and ataxia. Journal of Neuroscience Methods, 2016, 268, 171-181.	2.5	21
58	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
59	Impulsivity trait in the early symptomatic BACHD transgenic rat model of Huntington disease. Behavioural Brain Research, 2016, 299, 6-10.	2.2	25
60	FDG Î¼PET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease â€“ A 15 Months Follow-up Study. Journal of Huntington's Disease, 2015, 4, 37-47.	1.9	2
61	Reduction in Subventricular Zone-Derived Olfactory Bulb Neurogenesis in a Rat Model of Huntingtonâ€™s Disease Is Accompanied by Striatal Invasion of Neuroblasts. PLoS ONE, 2015, 10, e0116069.	2.5	34
62	HBOC multi-gene panel testing: comparison of two sequencing centers. Breast Cancer Research and Treatment, 2015, 152, 129-136.	2.5	38
63	Reduced impact of emotion on choice behavior in presymptomatic BACHD rats, a transgenic rodent model for Huntington Disease. Neurobiology of Learning and Memory, 2015, 125, 249-257.	1.9	15
64	Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. Brain, 2015, 138, 3632-3653.	7.6	36
65	Reduced Motivation in the BACHD Rat Model of Huntington Disease Is Dependent on the Choice of Food Deprivation Strategy. PLoS ONE, 2014, 9, e105662.	2.5	15
66	A behavioral comparison of the common laboratory rat strains Lister Hooded, Lewis, Fischer 344 and Wistar in an automated homecage system. Genes, Brain and Behavior, 2014, 13, 305-321.	2.2	33
67	Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington's disease. Journal of Neuroscience Methods, 2014, 234, 38-53.	2.5	45
68	Mitochondrial Membrane Fluidity is Consistently Increased in Different Models of Huntington Disease: Restorative Effects of Olesoxime. Molecular Neurobiology, 2014, 50, 107-118.	4.0	37
69	Altered diffusion tensor imaging measurements in aged transgenic Huntington disease rats. Brain Structure and Function, 2013, 218, 767-778.	2.3	19
70	Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Human Molecular Genetics, 2013, 22, 508-518.	2.9	70
71	A Novel Transgenic Rat Model for Spinocerebellar Ataxia Type 17 Recapitulates Neuropathological Changes and SuppliesIn VivoImaging Biomarkers. Journal of Neuroscience, 2013, 33, 9068-9081.	3.6	37
72	Automated home cage assessment shows behavioral changes in a transgenic mouse model of spinocerebellar ataxia type 17. Behavioural Brain Research, 2013, 250, 157-165.	2.2	7

#	Article	IF	Citations
73	The V471A Polymorphism in Autophagy-Related Gene ATG7 Modifies Age at Onset Specifically in Italian Huntington Disease Patients. PLoS ONE, 2013, 8, e68951.	2.5	49
74	Reversal Learning and Associative Memory Impairments in a BACHD Rat Model for Huntington Disease. PLoS ONE, 2013, 8, e71633.	2.5	24
75	Early Deficits in Glycolysis Are Specific to Striatal Neurons from a Rat Model of Huntington Disease. PLoS ONE, 2013, 8, e81528.	2.5	37
76	Modified impact of emotion on temporal discrimination in a transgenic rat model of Huntington disease. Frontiers in Behavioral Neuroscience, 2013, 7, 130.	2.0	17
77	Cerebellar Soluble Mutant Ataxin-3 Level Decreases during Disease Progression in Spinocerebellar Ataxia Type 3 Mice. PLoS ONE, 2013, 8, e62043.	2.5	18
78	Assessment of Motor Function, Sensory Motor Gating and Recognition Memory in a Novel BACHD Transgenic Rat Model for Huntington Disease. PLoS ONE, 2013, 8, e68584.	2.5	53
79	A Novel BACHD Transgenic Rat Exhibits Characteristic Neuropathological Features of Huntington Disease. Journal of Neuroscience, 2012, 32, 15426-15438.	3.6	89
80	Automated Behavioral Phenotyping Reveals Presymptomatic Alterations in a SCA3 Genetrap Mouse Model. Journal of Genetics and Genomics, 2012, 39, 287-299.	3.9	15
81	Genetic analysis of polymorphisms in the kalirin gene for association with age-at-onset in European Huntington disease patients. BMC Medical Genetics, 2012, 13, 48.	2.1	6
82	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
83	The Guanine Nucleotide Exchange Factor Kalirin-7 Is a Novel Synphilin-1 Interacting Protein and Modifies Synphilin-1 Aggregate Transport and Formation. PLoS ONE, 2012, 7, e51999.	2.5	10
84	Generation of a novel rodent model for DYT1 dystonia. Neurobiology of Disease, 2012, 47, 61-74.	4.4	70
85	Genotype specific age related changes in a transgenic rat model of Huntington's disease. NeuroImage, 2011, 58, 1006-1016.	4.2	22
86	1H NMR based metabolomics of CSF and blood serum: A metabolic profile for a transgenic rat model of Huntington disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1371-1379.	3.8	73
87	Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages. Neurobiology of Disease, 2011, 44, 192-204.	4.4	28
88	Functional changes in postsynaptic adenosine A2A receptors during early stages of a rat model of Huntington disease. Experimental Neurology, 2011, 232, 76-80.	4.1	15
89	Localization of sequence variations in PGC-1Î± influence their modifying effect in Huntington disease. Molecular Neurodegeneration, 2011, 6, 1.	10.8	97
90	N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. Brain, 2011, 134, 1925-1942.	7.6	52

#	Article	IF	Citations
91	Behavioral and In Vivo Electrophysiological Evidence for Presymptomatic Alteration of Prefrontostriatal Processing in the Transgenic Rat Model for Huntington Disease. Journal of Neuroscience, 2011, 31, 8986-8997.	3.6	64
92	Stem Cell Quiescence in the Hippocampal Neurogenic Niche Is Associated With Elevated Transforming Growth Factor-Î² Signaling in an Animal Model of Huntington Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 717-728.	1.7	86
93	Age at onset in Huntingtonâ€™s disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7. Human Genetics, 2010, 128, 453-459.	3.8	93
94	The regulation of OXPHOS by extramitochondrial calcium. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 1018-1027.	1.0	96
95	Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders. Journal of Proteomics, 2010, 73, 2230-2238.	2.4	39
96	Normal-Weight 14-Year-Old Girl with Acanthosis Nigricans and Markedly Increased Hepatic Steatosis: Evidence for the Important Role of Ectopic Fat Deposition in the Pathogenesis of Insulin Resistance in Childhood and Adolescence. Hormone Research in Paediatrics, 2010, 74, 376-380.	1.8	4
97	Cholesterol Defect Is Marked across Multiple Rodent Models of Huntington's Disease and Is Manifest in Astrocytes. Journal of Neuroscience, 2010, 30, 10844-10850.	3.6	136
98	Neurobehavioral Tests in Rat Models of Degenerative Brain Diseases. Methods in Molecular Biology, 2010, 597, 333-356.	0.9	31
99	Serum levels of a subset of cytokines show high interindividual variability and are not altered in rats transgenic for HuntingtonÂ's disease. PLOS Currents, 2010, 2, RRN1190.	1.4	7
100	Mitochondria and Energetic Depression in Cell Pathophysiology. International Journal of Molecular Sciences, 2009, 10, 2252-2303.	4.1	73
101	Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic Î±2-receptor levels in a transgenic Huntington's disease rat model. Behavioural Brain Research, 2009, 205, 175-182.	2.2	35
102	Mosaic Trisomy 21/Monosomy 21 in a Living Female Infant. Cytogenetic and Genome Research, 2009, 125, 26-32.	1.1	13
103	Subtle neurological and metabolic abnormalities in an Opa1 mouse model of autosomal dominant optic atrophy. Experimental Neurology, 2009, 220, 404-409.	4.1	44
104	Gene expression changes in a transgenic mouse model overexpressing human wildtype and mutant torsinA. Proteomics - Clinical Applications, 2008, 2, 720-736.	1.6	7
105	Ageâ€dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics - Clinical Applications, 2008, 2, 1638-1650.	1.6	17
106	Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: Restoration by the neuroprotective compound CEP-1347. Molecular and Cellular Neurosciences, 2008, 39, 1-7.	2.2	46
107	Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease. Journal of Neuroscience, 2008, 28, 2471-2484.	3.6	164
108	Impaired Regulation of Brain Mitochondria by Extramitochondrial Ca2+ in Transgenic Huntington Disease Rats. Journal of Biological Chemistry, 2008, 283, 30715-30724.	3.4	76

#	Article	IF	Citations
109	Sex differences in a transgenic rat model of Huntington's disease: decreased 17Î²-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Human Molecular Genetics, 2008, 17, 2595-2609.	2.9	114
110	Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. Human Molecular Genetics, 2008, 17, 1137-1146.	2.9	78
111	Cellular and subcellular localization of Huntington aggregates in the brain of a rat transgenic for Huntington disease. Journal of Comparative Neurology, 2007, 501, 716-730.	1.6	77
112	Overexpression of human wildtype torsinA and human Î”GAG torsinA in a transgenic mouse model causes phenotypic abnormalities. Neurobiology of Disease, 2007, 27, 190-206.	4.4	123
113	Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington's disease transgenic ratmodel. Behavioural Brain Research, 2006, 170, 257-261.	2.2	53
114	Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. Neurobiology of Disease, 2006, 22, 538-547.	4.4	65
115	Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Human Molecular Genetics, 2006, 15, 3177-3194.	2.9	109
116	Transgenic rat model of Huntington's disease. Human Molecular Genetics, 2003, 12, 617-624.	2.9	329
117	Factors influencing behavior of group-housed male rats in the social interaction test. Physiology and Behavior, 2001, 74, 277-282.	2.1	38